ASP1707

DRUG5 trials

Sponsors

Astellas Pharma Europe B.V., Astellas Pharma Global Development, Inc., Astellas Pharma Inc

Conditions

DDI (Drug-Drug Interaction)EndometriosisHealthy SubjectsPharmacokineticsRheumatoid Arthritis

Phase 1

A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects

CompletedNCT02146742

Astellas Pharma Europe B.V.Healthy Subjects

Start: 2011-06-30End: 2011-08-31Updated: 2014-05-26

A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects

CompletedNCT02175407

Astellas Pharma Europe B.V.DDI (Drug-Drug Interaction), Healthy Subjects, Pharmacokinetics

Start: 2014-04-30End: 2014-06-30Updated: 2014-07-03

A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis

CompletedNCT02867306

Astellas Pharma Global Development, Inc.Rheumatoid Arthritis

Start: 2016-07-25End: 2016-08-30Updated: 2024-10-23

Phase 2

A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

CompletedNCT01767090

Astellas Pharma Europe B.V.Endometriosis

Start: 2012-12-04End: 2015-07-30Updated: 2024-10-23

A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate

CompletedNCT02884635

Astellas Pharma IncRheumatoid Arthritis

Start: 2016-09-16End: 2017-10-25Updated: 2024-10-23

Related Papers

A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate.

2020-03-032 citations

Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.

2019-05-0112 citations